This experimental study examined the effect of the antioxidant drug U-74389G, on a rat model and particularly in a renal ischemia-reperfusion protocol. The effects of that molecule were studied biochemically using blood mean urea levels. Forty rats of mean weight 231.875 g were used in the study. Urea levels were measured at 60 min of reperfusion (groups A and C) and at 120 min of reperfusion (groups B and D). The drug U-74389G was administered only in groups C and D. U-74389G administration significantly decreased the predicted urea levels by 11.35%±2.73% (P=0.0001). Reperfusion time non-significantly increased the predicted urea levels by 2.26%±3.29% (P=0.4103). However, U-74389G administration and reperfusion time together significantly decreased the predicted urea levels by 6.31%±1.70% (P=0.0005). U-74389G administration whether it interacted or not with reperfusion time had significant decreasing effect on the urea serum levels, reflecting a respective renal function augmentation.
Introduction
Permanent or transient damage with serious implications on adjacent organs and systems may be due to tissue ischemia-reperfusion (IR). The use of U-74389G in IR has been a challenge for many years. However, although the progress was significant, several practical questions have not clarified. They include: i) how potent U-74389G should be; ii) when should it be administered; and iii) at what optimal dose of U-74389G should be administered. The promising effect of U-74389G in tissue protection has been noted in several IR studies. U-74389G or also known as 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-pregna-1,4,9(11)-triene-3,20-dione maleate salt is an antioxidant which prevents both arachidonic acid-induced and iron-dependent lipid peroxidation. 1 It protects against IR injury in animal organs such as heart, liver and kidney models. These membrane-associating antioxidants are particularly effective in preventing permeability changes in brain microvascular endothelial cells monolayers. 2 A meta-analysis of 20 published seric variables, coming from the same experimental setting, tried to provide a numeric evaluation of the U-74389G efficacy at the same endpoints (Table 1) . Several publications addressed trials of other similar antioxidant molecules to which the studied molecule U-74389G belongs.
The aim of this experimental study was to examine the effect of the antioxidant drug U-74389G on rat model and particularly in a renal IR protocol. The effects of that molecule were studied by measuring blood mean serum urea levels.
Materials and Methods

Animal preparation
This basic experimental research was licensed by
The effect of the antioxidant drug U-74389G on urea levels during ischemia reperfusion injury in rats N o n -c o m m e r c i a l u s e o n l y [3] [4] [5] [6] [7] oxygen supply, electrocardiogram and acidometry. Post-experimental awakening and preservation of animals were not permitted, even if euthanasia was needed. Rats were randomly delivered to four experimental groups by 10 animals in each one, using following protocols of IR: ischemia for 45 min followed by reperfusion for 60 min (group A); ischemia for 45 min followed by reperfusion for 120 min (group B); ischemia for 45 min followed by immediate U-74389G intravenous (IV) administration and reperfusion for 60 min (group C); ischemia for 45 min followed by immediate U-74389G IV administration and reperfusion for 120 min (group D). The dose of U-74389G was 10 mg/kg body mass of animals. Ischemia was caused by laparotomic clamping inferior aorta over renal arteries with forceps for 45 min. Reperfusion was induced by removing the clamp and re-establishing inferior aorta patency. U-74389G was administered at the time of reperfusion; through catheterized inferior vena cava. The urea levels were determined at 60 th min of reperfusion (for A and C groups) and at 120 th min of reperfusion (for B and D groups). Forty female Wistar albino rats were used (mean weight 231.875 g [standard deviation (SD): 36.59703 g], with minimum weight 165 g and maximum weight 320 g. Rats weight could be potentially a confusing factor, e.g. more obese rats have higher urea levels. This assumption was also investigated.
[ 
Lazaroid (L) group
Twenty L rats (mean mass 211.25 g [SD: 17.53755 g] experienced ischemia for 45 min followed by reperfusion in the beginning of which 10 mg U-74389G /kg body weight were IV administered. 
Statistical analysis
Every weight and urea level group was compared with each other by statistical standard t-tests. Any significant difference among urea levels, was investigated due to weight fluctuation. The application of generalized linear models (glm) with dependent variable with urea levels as the dependant variable was followed. The 3 independent variables were the U-74389G or no drug, the reperfusion time and both variables in combination. Inserting the rats weight also as an independent variable at glm analysis, a significant relation resulted in (P=0.0030), so as to further investigation was needed. The predicted urea values for weight were calculated and are depicted in Table  2 . The differences between predicted urea values groups calculated by standard t test are depicted in Table 3 . The application of glm was followed with dependent variable used the predicted urea levels. The 3 independent variables were the same as in first glm.
Results
The first glm resulted in: U-74389G administration significantly decreased the urea levels by 11.6 mg/dL [-18 The effect of the antioxidant drug U-74389G on urea levels in rats The second glm resulted in: U-74389G administration significantly decreased the predicted urea levels by 6.529913 mg/dL [-9 .615044 mg/dL --3.444781 mg/dL] (P=0.0001). This finding was in accordance with the results of standard t-test (P=0.0002). Reperfusion time non-significantly increased the predicted urea levels by 1.305982 mg/dL [-2.426665 mg/dL -5.038628 mg/dL] (P=0.4831), also in accordance with standard t-test (P=0.3375). However, U-74389G administration and reperfusion time together significantly decreased the predicted urea levels by 3.633726 mg/dL [-5 .559681 mg/dL --1.707771 mg/dL] (P=0.0005). Reviewing the above and Table 3, the Tables 4 and 5 sumup concern the decreasing influence of U-74389G in connection with reperfusion time.
Discussion
Serum urea is considered one of the two renal function indexes. Renal function is influenced by ischemia particularly by certain mode, as the next references show. Xu et al. 8 found urea serum concentrations significantly elevated after 45 min of kidneys IR in male Sprague-Dawley rats. Cakmaz et al. 9 found the extent of increased plasma D-amino acid oxidase levels and the one of decreased citrulline levels dependent on superior mesenteric artery IR in Wistar albino rats. Koetting et al. significantly enhanced 10 the renal function by 2 h hypothermic machine reperfusion with oxygenation HR-O = more than threefold increase in renal clearances of urea levels, after cold stored kidneys preservation; in female German Landrace pigs. Oliveira et al. investigated 11 the mechanisms involved in the protective activity of IV FTY720 (1 mg/kg) immediately before renal IR injury model about short-term (24 h) function outcome. Medina et al. found no difference in the degree of renal failure analyziing 12 serum urea levels at shortterm kidneys IR between IGF-I50 μg/100 g reperfusion treatment than untreated controls male rats. Ansermet et al. 13 found plasma urea levels not depressed after the higher doses of toxic agents measured within 48 h after either mercuric chloride, or gentamicin, or tobramycin administration or renal arteries IR in adult male Wistar rats. Lin et al.
14 noted no significant difference in the urea kinetic study treating erythropoietin-hyporesponsive anemia by IV ascorbic acid in chronic hemodialysis patients with type II diabetes.
Also, urea is a factor influenced by U-74389G. Suitable U-74389G administration can indirectly cure ischemic cases. The following clinical situations can show this more clearly. Alhan et al. 15 inhibited the significant increase in urea levels induced due to acute necrotizing pancreatitis in rats treated by the use of U-74389G. Hori et al. 16 designed the present study in order to investigate whether U-74389G has a protective effect on 0.9 mg/kg IV cisplatin (CDDP)-induced nephrotoxicity in Fisher rats. No significant difference in serum blood urea nitrogen level between control and case groups was noted. U-74389G was found not to ameliorate cisplatin CDDP-induced nephrotoxicity.
Conclusions
U-74389G administration whether it interacted or not with reperfusion time had significant decreasing effect on the serum urea levels, reflecting a respective renal urea excretion augmentation.
